The Johns Hopkins University

Other

Novartis Ag

Allergan, Inc.

Mirna Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc.

Ciba Vision Corporation

Asuragen, Inc.

Nacuity Pharmaceuticals, Inc.

Alimera Sciences, Inc.

Novartis Pharma Gmbh

Peter Anthony Campochiaro

Roshantha A Chandraratna

Larry Allen Wheeler

Justin Scot Hanes

Sunil Nagpal

Jie Fu

Romulus Kimbro Brazzell

Jikui Shen

David Allen Brown

Kevin Kelnar

Eugene De Juan, Jr

Jeffrey Shelton

Michael Kaleko

Tianci Luo

Jeanette Marjorie Wood

Frances Elizabeth Kane

Lili Lu

Katharine Hilary Dixon

George D Yancopoulos

Stanley J Wiegand

Jordan J Green

Donald Jeffrey Zack

Peter Louis Gehlbach

Jayoung Kim

Kenneth E Green

Daniel Hartman

Yogita Kanan

Craig S Rosenfeld

David Brown

The present invention includes a method for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA). In accordance with an embodiment, the present invention provides a method for the treatment of retinitis pigmentosa in an animal that comprises administering to the animal a therapeutically effective amount of N-acetylcystein amide (NACA).

Treatment of retinitis pigmentosa with n-acetylcysteine amide

The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

Biomarkers useful in the treatment of subjects having diseases of the eye

The presently disclosed subject matter provides compositions and methods for administering a nanoparticle or microparticle and a therapeutic agent to the suprachoroidal space in the eye.

Nonviral gene transfer to the suprachoroidal space

Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.

Non-linear multiblock copolymer-drug conjugates for the delivery of active agents

A method of treating or inhibiting degeneration of a retina of a subject in need thereof comprising administering an effective amount of a compound of metipranolol, or a metabolite thereof, to an organ, a tissue, or the subject, wherein the degeneration of the retina is caused by an ocular disease. In some embodiments, the compound, or a metabolite thereof, is administered topically, orally, or parenterally. In some embodiments, a drug delivery vehicle comprising a dosage of the compound, or the metabolite of, is delivered parenterally via intravitreal injection. In further embodiments, the dosage may range from 0.5 &#x3bc;g/day-15 &#x3bc;g/day.

Methods of treating retinal diseases

Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.

Controlled release formulations for the delivery of HIF-1 inhibitors

The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed.

Compositions and methods related to miRNA modulation of neovascularization or angiogenesis

Methods are provided for the treatment of ocular neovascularization by increasing, in an individual afflicted with ocular neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to an ocular neovascularization inhibiting effective amount, where the endostatin protein has anti-ocular neovascularization activity in vivo.

Method for treating ocular neovascularization

Growing community of inventors

Baltimore, MD, United States of America

Peter Anthony Campochiaro